Inhibition of MACC1-Induced Metastasis in Esophageal and Gastric Adenocarcinomas
Authors:
- Christoph TreeseCTChristoph Treese
- Jessica WerchanJWJessica Werchan
- Moritz von WinterfeldMWMoritz von Winterfeld
- Erika BergEBErika Berg
- Michael HummelMHMichael Hummel
- Lena TimmLTLena Timm
- Beate RauBeate Rau
- Ole DaberkowODOle Daberkow
- Wolfgang WaltherWWWolfgang Walther
- Severin DaumSDSeverin Daum
- Dennis KobeltDKDennis Kobelt
- Ulrike SteinUlrike Stein
Open Access
Abstract
Esophageal and Gastric Adenocarcinomas (AGE/S) are characterized by early metastasis and poor survival. MACC1 (Metastasis Associated in Colon Cancer 1) acts in colon cancer as a metastasis inducer and is linked to reduced survival. This project illuminates the role and potential for the inhibition of MACC1 in AGE/S. Using 266 of 360 TMAs and survival data of AGE/S patients, we confirm the value of MACC1 as an independent negative prognostic marker in AGE/S patients. MACC1 gene expression is correlated with survival and morphological characteristics. In vitro analysis of lentivirally MACC1-manipulated subclones of FLO-1 and OE33 showed enhanced migration induced by MACC1 in both cell line models, which could be inhibited by the MEK1 inhibitor selumetinib. In vivo, the efficacy of selumetinib on tumor growths and metastases of MACC1-overexpressing FLO-1 cells xenografted intrasplenically in NOG mice was tested. Mice with high-MACC1-expressing cells developed faster and larger distant metastases. Treatment with selumetinib led to a significant reduction in metastasis exclusively in the MACC1-positive xenografts. MACC1 is an enhancer of tumor aggressiveness and a predictor of poor survival in AGE/S. This effect can be inhibited by selumetinib.Keywords
Funding Information
- Berlin Society of Cancer “Berliner Krebsgesellschaft” (TRFF201501)
- Charité - University Medicine Berlin and the Berlin Institute of Health (Charité Clinical Scientist Program)
This publication has 36 references indexed in Scilit:
- Expression of MACC1 and c-Met in human gastric cancer and its clinical significanceCancer Cell International, 2013
- Prognostic Value and Clinical Pathology of MACC-1 and c-MET Expression in Gastric CarcinomaPathology and Oncology Research, 2013
- Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasionInternational Journal of Cancer, 2013
- The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in OncologyYonsei Medical Journal, 2013
- In vivo imaging of colorectal cancer growth and metastasis by targeting MACC1 with shRNA in xenografted miceClinical & Experimental Metastasis, 2012
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III StudyJournal of Clinical Oncology, 2011
- Over-expression of metastasis-associated in colon cancer-1 (MACC1) associates with better prognosis of gastric cancer patientsChinese Journal of Cancer Research, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasisNature Medicine, 2008
- Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systemsBritish Journal of Cancer, 2002